EMA issues positive opinion on Novo Nordisk's higher-dose Wegovy, supported by strong weight-loss data and ongoing reviews in ...
This follows recent successful efforts by the Trump administration to cut the price of this compound for certain patients.
Regulators in Europe just backed Novo's heavyweight Wegovy--setting the stage for a head-to-head obesity drug showdown in ...
Novo Nordisk said on Friday the European Medicines Agency's committee had issued a positive opinion for a higher dose of its ...
The Subject Expert Committee (SEC) under the Central Drugs Standard Control Organisation (CDSCO) has recommended granting approval to Novo Nordisk India for its proposed update to ...
Novo Nordisk ( NVO 2.28%) stock was slimming down on Monday, but not in the way any investor in the Wegovy and Ozempic ...
Today, the European Medicines Agency’s Committee for Medicinal Products for Human Use, CHMP, issued a positive opinion for a ...
Novo Nordisk's Wegovy consumption jumped 70% after price cuts, lifting share in November. Eli Lilly's Mounjaro still led anti ...
The European Medicines Agency (EMA) has issued a positive opinion for a new Wegovy® 7.2 mg dose, advancing its availability ...
How much Novo Nordisk’s weight-loss drug Wegovy costs can depend on a lot of things, which makes it very hard for the average ...
Dec 2 () - Wegovy maker Novo Nordisk is planning to test its experimental obesity drug, CagriSema, in overweight children ...
A peripherally acting cannabinoid receptor 1 antibody combined with semaglutide induced significant weight loss for adults ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback